Branded pharmaceutical manufacturers frequently offer "copay coupons" that insulate consumers from cost-sharing, thereby undermining insurers' ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and 2010. To overcome endogeneity concerns, we exploit cross-state and cross-consumer variation in coupon legality. We find that coupons increase branded sales by 60+ percent, entirely by reducing the sales of bioequivalent generics. During the five years following generic entry, we estimate that coupons increase total spending by $30 to $120 million per drug, or $700 million to $2.7 billion for our sample alone.
Dafny, Leemore, Christopher Ody, and Matt Schmitt.
"When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization."
American Economic Journal: Economic Policy,
Insurance; Insurance Companies; Actuarial Studies
Health Insurance, Public and Private
Production, Pricing, and Market Structure; Size Distribution of Firms
Chemicals; Plastics; Rubber; Drugs; Biotechnology